Bioceres Crop Solutions (BIOX) fiscal Q4 2026: microbeaded fertilizer stabilizes revenue as inventory charges mask margin progress

Microbeaded fertilizer throughput carried Bioceres Crop Solutions (BIOX) to fourth-quarter revenues of $55.9 million, nearly matching the $55.4 million reported in the same period a year ago, as Crop Nutrition volume rose 36% and offset weaker crop protection and seed results. A $4 million nonrecurring inventory obsolescence charge compressed reported gross margin to 22.8% and, according to CFO Ezequiel Simmermacher, masked genuine improvement across several core product categories. The next milestone on the setup is management's fiscal 2027 target of approximately 40% gross margins, which CEO Federico Trucco said is contingent on concentrating growth on higher-quality core revenue streams, with Brazil named as a priority.

Quarterly and full-year operating results

Beneath the headline, microbeaded fertilizer drove both revenue and margin gains inside Crop Nutrition, where gross profit rose 37% for the quarter. The adjuvants portfolio within crop protection delivered higher gross profit and improved margins despite lower segment revenues overall. Seed treatment packs contributed approximately 40% gross profit growth in the period. Adjusted EBITDA for the quarter swung from negative $9.6 million to positive $600 thousand year over year, with SG&A down 19% as cost actions taken throughout fiscal 2026 cleared through the income statement.

For the full year, revenues fell 18% to $238 million. Simmermacher said roughly half that decline traced to the wind-down of the prior seed business model, with most of the remaining shortfall in crop protection. Reported full-year gross profit was $82.9 million, down 21%, at a 34.8% margin. Full-year adjusted EBITDA came in at $25.5 million, against $28.9 million in fiscal 2025, a 12% decline despite the larger revenue and gross profit drops. Trucco noted that 99% of aggregated fiscal 2025 gross profit came from fewer than half the catalog's SKUs, framing the ongoing portfolio rationalization as the mechanism behind the 40% margin target.

Capital structure and litigation

Total financial debt at June 30 stood at $225.9 million, against cash and short-term investments of $12.2 million, for net financial debt of $213.6 million. Of that balance, $118.6 million in secured notes remains classified as short-term after certain noteholders accelerated obligations tied to a dispute now before New York courts. Bioceres is contesting the acceleration. During the fourth quarter, Rizobacter completed a reprofiling of approximately $28 million in bank debt, and a voluntary maturity extension covered $46.5 million in Argentine local bond principal. Management is separately targeting a combined SG&A ratio of 23% of revenues by fiscal 2028, with organizational simplification as the stated path. Resolving, or negotiating an alternative to, the New York proceedings is the capital-structure variable heading into fiscal 2027.